1. Home
  2. SCSC vs ANL Comparison

SCSC vs ANL Comparison

Compare SCSC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ScanSource Inc.

SCSC

ScanSource Inc.

N/A

Current Price

$44.18

Market Cap

869.5M

Sector

Technology

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.63

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SCSC
ANL
Founded
1992
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
869.5M
998.8M
IPO Year
1997
2022

Fundamental Metrics

Financial Performance
Metric
SCSC
ANL
Price
$44.18
$10.63
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
★ $64.50
$29.50
AVG Volume (30 Days)
★ 316.4K
280.6K
Earning Date
11-05-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 21.33
N/A
EPS
★ 0.42
N/A
Revenue
★ $3,846,260,000.00
N/A
Revenue This Year
$12.92
$243.83
Revenue Next Year
$5.96
N/A
P/E Ratio
$106.36
★ N/A
Revenue Growth
★ 7.79
N/A
52 Week Low
$33.76
$0.88
52 Week High
$66.78
$17.25

Technical Indicators

Market Signals
Indicator
SCSC
ANL
Relative Strength Index (RSI) 25.12 44.99
Support Level $34.23 $8.95
Resistance Level $46.64 $11.90
Average True Range (ATR) 2.78 0.95
MACD -1.57 0.22
Stochastic Oscillator 18.03 62.75

Price Performance

Historical Comparison
SCSC
ANL

About SCSC ScanSource Inc.

ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: